SG Americas Securities
SNNA

SG Americas Securities’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

SG Americas Securities’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-33,450
Closed -$78K – 3740
2018
Q4 		$78K Buy
+33,450
New +$295K ﹤0.01% 2771

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SG Americas Securities's SNNA Position: Q1 2019 in Review

SG Americas Securities sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2019, closing a stake of 33,450 shares — an estimated $78K sold.

SG Americas Securities first reported a position in SNNA in Q4 2018 and held it in 1 quarter. The position peaked at $78K in Q4 2018. 57 funds tracked by Wall St. Rank hold SNNA as of Q1 2019.

  • SG Americas Securities reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • SG Americas Securities sold 33,450 Sienna Biopharmaceuticals, Inc. shares in Q1 2019, an estimated $78K.
  • SG Americas Securities first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • SG Americas Securities's Sienna Biopharmaceuticals, Inc. position peaked at $78K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2019.

Based on SG Americas Securities's 13F filing for Q1 2019, filed 29 Apr 2019.